Drug intelligence / Profile preview

OPN-9627

Development stage: Preclinical
Lead developer: Opna Bio
Modality: Small Molecules
Administration: Oral

Overview

OPN-9627 is an orally available, small molecule inhibitor of CD73 (ecto-5'-nucleotidase), developed by Opna Bio. It is designed to block the adenosine pathway in the tumor microenvironment, thereby preventing immune evasion by cancer cells. By inhibiting CD73, which catalyzes the conversion of AMP to immunosuppressive adenosine, OPN-9627 aims to enhance anti-tumor immune responses and may act synergistically with checkpoint inhibitors. The drug is being developed for gastrointestinal cancers including gastric, liver, pancreatic, and colorectal cancer (CRC). As of early 2025, it remains in preclinical or discovery stages[1][3].

Other names: OPN-CD73OPN-CD-73OPN-CD 73

Targets

NT5E (Cluster of Differentiation 73)

Beyond the preview

Go deeper on OPN-9627.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OPN-9627.

Explore the full profile